Signaling pathways in renal cell carcinoma

References

• Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22:454 - 463
   PubMed Web of Science ®Google Scholar
• Grossman E, Messerli FH. Diuretics and renal cell carcinoma—What is the risk/benefit ratio?. Kidney Int 1999; 56:1603 - 1604
   PubMed Web of Science ®Google Scholar
• Pavlovich CP, Schmidt LS. Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer 2004; 4:381 - 393
   PubMed Web of Science ®Google Scholar
• Zbar B, Klausner R, Linehan WM. Studying cancer families to identify kidney cancer genes. Annu Rev Med 2003; 54:217 - 233
   PubMed Web of Science ®Google Scholar
• McRonald FE, Morris MR, Gentle D, Winchester L, Baban D, Ragoussis J, et al. CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. Mol Cancer 2009; 8:31
   PubMed Web of Science ®Google Scholar
• Ratcliffe PJ. New insights into an enigmatic tumour suppressor. Nat Cell Biol 2003; 5:7 - 8
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002; 2:673 - 682
   PubMed Web of Science ®Google Scholar
• Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999; 18:2343 - 2350
   PubMed Web of Science ®Google Scholar
• Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353:2477 - 2490
   PubMed Web of Science ®Google Scholar
• Valladares Ayerbes M, Aparicio Gallego G, Diaz Prado S, Jimenez Fonseca P, Garcia Campelo R, Anton Aparicio LM. Origin of renal cell carcinomas. Clin Transl Oncol 2008; 10:697 - 712
   PubMed Web of Science ®Google Scholar
• Kiuru M, Lehtonen R, Arola J, Salovaara R, Jarvinen H, Aittomaki K, et al. Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res 2002; 62:4554 - 4557
   PubMed Web of Science ®Google Scholar
• Gad S, Lefevre SH, Khoo SK, Giraud S, Vieillefond A, Vasiliu V, et al. Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma. Br J Cancer 2007; 96:336 - 340
   PubMed Web of Science ®Google Scholar
• Polascik TJ, Cairns P, Epstein JI, Fuzesi L, Ro JY, Marshall FF, et al. Distal nephron renal tumors: micro-satellite allelotype. Cancer Res 1996; 56:1892 - 1895
   PubMed Web of Science ®Google Scholar
• Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 2010; 7:277 - 285
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441:424 - 430
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324:1029 - 1033
   PubMed Web of Science ®Google Scholar
• Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26:225 - 239
   PubMed Web of Science ®Google Scholar
• Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, prognosis and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 2003; 9:4641 - 4652
   PubMed Web of Science ®Google Scholar
• Clifford SC, Walsh S, Hewson K, Green EK, Brinke A, Green PM, et al. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development. Genes Chromosomes Cancer 1999; 26:20 - 28
   PubMed Web of Science ®Google Scholar
• Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29:625 - 634
   PubMed Web of Science ®Google Scholar
• Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721 - 732
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr. The von Hippel-Lindau protein, HIF hydroxylation and oxygen sensing. Biochem Biophys Res Commun 2005; 338:627 - 638
   PubMed Web of Science ®Google Scholar
• Kaelin WG. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing. Cold Spring Harb Symp Quant Biol 2005; 70:159 - 166
   PubMedGoogle Scholar
• Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009; 6:587 - 595
   PubMed Web of Science ®Google Scholar
• Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008; 14:435 - 446
   PubMed Web of Science ®Google Scholar
• Bertout JA, Majmundar AJ, Gordan JD, Lam JC, Ditsworth D, Keith B, et al. HIF2alpha inhibition promotes p53 pathway activity, tumor cell death and radiation responses. Proc Natl Acad Sci USA 2009; 106:14391 - 14396
   PubMed Web of Science ®Google Scholar
• Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002; 64:993 - 998
   PubMed Web of Science ®Google Scholar
• Sun Q, Zhou H, Binmadi NO, Basile JR. Hypoxia-inducible factor-1-mediated regulation of semaphorin 4D affects tumor growth and vascularity. J Biol Chem 2009; 284:32066 - 32074
   PubMed Web of Science ®Google Scholar
• Kluger HM, Siddiqui SF, Angeletti C, Sznol M, Kelly WK, Molinaro AM, et al. Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Lab Invest 2008; 88:962 - 972
   PubMed Web of Science ®Google Scholar
• Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E. Carbonic Anhydrase IX in Renal Cell Carcinoma: Implications for Prognosis, Diagnosis and Therapy. Eur Urol 2010; 58:75 - 83
   PubMed Web of Science ®Google Scholar
• Juan D, Alexe G, Antes T, Liu H, Madabhushi A, Delisi C, et al. Identification of a microRNA panel for clear-cell kidney cancer. Urology 2009; 75:835 - 841
   PubMed Web of Science ®Google Scholar
• Jung M, Mollenkopf HJ, Grimm C, Wagner I, Albrecht M, Waller T, et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med 2009;
   Web of Science ®Google Scholar
• Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 2009; 35:856 - 867
   PubMed Web of Science ®Google Scholar
• del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997; 278:687 - 689
   PubMed Web of Science ®Google Scholar
• Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282:1318 - 1321
   PubMed Web of Science ®Google Scholar
• Kim AH, Khursigara G, Sun X, Franke TF, Chao MV. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol 2001; 21:893 - 901
   PubMed Web of Science ®Google Scholar
• Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12:3499 - 3511
   PubMed Web of Science ®Google Scholar
• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471 - 484
   PubMed Web of Science ®Google Scholar
• Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926 - 1945
   PubMed Web of Science ®Google Scholar
• Lin F, Zhang PL, Yang XJ, Prichard JW, Lun M, Brown RE. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. Ann Clin Lab Sci 2006; 36:283 - 293
   PubMed Web of Science ®Google Scholar
• Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95:29 - 39
   PubMed Web of Science ®Google Scholar
• Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J, et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA 1999; 96:6199 - 6204
   PubMed Web of Science ®Google Scholar
• Testa JR, Tsichlis PN. AKT signaling in normal and malignant cells. Oncogene 2005; 24:7391 - 7393
   PubMed Web of Science ®Google Scholar
• Hara S, Oya M, Mizuno R, Horiguchi A, Marumo K, Murai M. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol 2005; 16:928 - 933
   PubMed Web of Science ®Google Scholar
• Cairns P, Evron E, Okami K, Halachmi N, Esteller M, Herman JG, et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 1998; 16:3215 - 3218
   PubMed Web of Science ®Google Scholar
• Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982; 31:99 - 109
   PubMed Web of Science ®Google Scholar
• Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006; 5:997 - 1014
   PubMed Web of Science ®Google Scholar
• Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127:469 - 480
   PubMed Web of Science ®Google Scholar
• Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 2009; 69:4674 - 4681
   PubMed Web of Science ®Google Scholar
• Furge KA, Chen J, Koeman J, Swiatek P, Dykema K, Lucin K, et al. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res 2007; 67:3171 - 3176
   PubMed Web of Science ®Google Scholar
• Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006; 126:955 - 968
   PubMed Web of Science ®Google Scholar
• Kim YS, Kang YK, Kim JB, Han SA, Kim KI, Paik SR. beta-catenin expression and mutational analysis in renal cell carcinomas. Pathol Int 2000; 50:725 - 730
   PubMed Web of Science ®Google Scholar
• Sansom OJ, Griffiths DF, Reed KR, Winton DJ, Clarke AR. Apc deficiency predisposes to renal carcinoma in the mouse. Oncogene 2005; 24:8205 - 8210
   PubMed Web of Science ®Google Scholar
• Qian CN, Knol J, Igarashi P, Lin F, Zylstra U, Teh BT, et al. Cystic renal neoplasia following conditional inactivation of apc in mouse renal tubular epithelium. J Biol Chem 2005; 280:3938 - 3945
   Google Scholar
• Saadi-Kheddouci S, Berrebi D, Romagnolo B, Cluzeaud F, Peuchmaur M, Kahn A, et al. Early development of polycystic kidney disease in transgenic mice expressing an activated mutant of the beta-catenin gene. Oncogene 2001; 20:5972 - 5981
   Google Scholar
• Battagli C, Uzzo RG, Dulaimi E, Ibanez de Caceres I, Krassenstein R, et al. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res 2003; 63:8695 - 8699
   PubMed Web of Science ®Google Scholar
• Peruzzi B, Athauda G, Bottaro DP. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proc Natl Acad Sci USA 2006; 103:14531 - 14536
   PubMed Web of Science ®Google Scholar
• Kojima T, Shimazui T, Hinotsu S, Joraku A, Oikawa T, Kawai K, et al. Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling. Oncogene 2009; 28:297 - 305
   PubMed Web of Science ®Google Scholar
• Awakura Y, Nakamura E, Ito N, Kamoto T, Ogawa O. Methylation-associated silencing of SFRP1 in renal cell carcinoma. Oncol Rep 2008; 20:1257 - 1263
   PubMed Web of Science ®Google Scholar
• Hirata H, Hinoda Y, Nakajima K, Kawamoto K, Kikuno N, Kawakami K, et al. Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways. Clin Cancer Res 2009; 15:5678 - 5687
   PubMed Web of Science ®Google Scholar
• Hirata H, Hinoda Y, Nakajima K, Kikuno N, Yamamura S, Kawakami K, et al. Wnt antagonist gene polymorphisms and renal cancer. Cancer 2009; 115:4488 - 4503
   PubMed Web of Science ®Google Scholar
• Kawakami K, Hirata H, Yamamura S, Kikuno N, Saini S, Majid S, et al. Functional significance of Wnt inhibitory factor-1 gene in kidney cancer. Cancer Res 2009; 69:8603 - 8610
   PubMed Web of Science ®Google Scholar
• Urakami S, Shiina H, Enokida H, Kawakami T, Tokizane T, Ogishima T, et al. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin Cancer Res 2006; 12:383 - 391
   PubMed Web of Science ®Google Scholar
• Linehan WM, Rubin JS, Bottaro DP. VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. Int J Biochem Cell Biol 2009; 41:753 - 756
   PubMed Web of Science ®Google Scholar
• Chitalia VC, Foy RL, Bachschmid MM, Zeng L, Panchenko MV, Zhou MI, et al. Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL. Nat Cell Biol 2008; 10:1208 - 1216
   PubMed Web of Science ®Google Scholar
• Berndt JD, Moon RT, Major MB. Beta-catenin gets jaded and von Hippel-Lindau is to blame. Trends Biochem Sci 2009; 34:101 - 104
   PubMed Web of Science ®Google Scholar
• Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 2008; 10:295 - 305
   PubMed Web of Science ®Google Scholar
• Rivera MN, Haber DA. Wilms' tumour: connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer 2005; 5:699 - 712
   PubMed Web of Science ®Google Scholar
• Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7:131 - 142
   PubMed Web of Science ®Google Scholar
• Dulaimi E, Ibanez de Caceres I, Uzzo RG, Al-Saleem T, Greenberg RE, Polascik TJ, et al. Promoter hypermethylation profile of kidney cancer. Clin Cancer Res 2004; 10:3972 - 3979
   PubMed Web of Science ®Google Scholar
• Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, et al. Genome-wide microRNA expression profiling in renal cell carcinoma: significant downregulation of miR-141 and miR-200c. J Pathol 2008; 216:418 - 427
   PubMed Web of Science ®Google Scholar
• Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10:593 - 601
   PubMed Web of Science ®Google Scholar
• Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9:582 - 589
   PubMed Web of Science ®Google Scholar
• Park SM, Gaur AB, Lengyel E, Peter ME. The miR200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22:894 - 907
   PubMed Web of Science ®Google Scholar
• Weber K, Doucet M, Kominsky S. Renal cell carcinoma bone metastasis—elucidating the molecular targets. Cancer Metastasis Rev 2007; 26:691 - 704
   PubMed Web of Science ®Google Scholar
• Wendt MK, Allington TM, Schiemann WP. Mechanisms of the epithelial-mesenchymal transition by TGFbeta. Future Oncol 2009; 5:1145 - 1168
   PubMed Web of Science ®Google Scholar
• Peruzzi B, Jean-Baptiste L, Bottaro DP. Bukowski RM, Figlin RA, Motzer RJ. The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma. Renal Cell Carcinoma: Humana Press 2009; 327
   Google Scholar
• Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16:68 - 73
   PubMed Web of Science ®Google Scholar
• Schmidt LS, Nickerson ML, Angeloni D, Glenn GM, Walther MM, Albert PS, et al. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met protooncogene. J Urol 2004; 172:1256 - 1261
   PubMed Web of Science ®Google Scholar
• Fischer J, Palmedo G, von Knobloch R, Bugert P, Prayer-Galetti T, Pagano F, et al. Duplication and overexpression of the mutant allele of the MET protooncogene in multiple hereditary papillary renal cell tumours. Oncogene 1998; 17:733 - 739
   PubMed Web of Science ®Google Scholar
• Giubellino A, Linehan WM, Bottaro DP. Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther 2009; 9:785 - 793
   PubMed Web of Science ®Google Scholar
• Toschi L, Janne PA. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. Clin Cancer Res 2008; 14:5941 - 5946
   PubMed Web of Science ®Google Scholar
• Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-MET signaling pathway in cancer. Clin Cancer Res 2009; 15:2207 - 2214
   PubMed Web of Science ®Google Scholar
• Monga SP, Mars WM, Pediaditakis P, Bell A, Mule K, Bowen WC, et al. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res 2002; 62:2064 - 2071
   PubMed Web of Science ®Google Scholar
• Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010; 463:360 - 363
   PubMed Web of Science ®Google Scholar
• Cairns P, Tokino K, Eby Y, Sidransky D. Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas. Cancer Res 1995; 55:224 - 227
   PubMed Web of Science ®Google Scholar
• Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003; 9:407 - 415
   PubMed Web of Science ®Google Scholar
• Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci 2007; 120:3163 - 3172
   PubMed Web of Science ®Google Scholar
• Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3:11 - 22
   PubMed Web of Science ®Google Scholar
• Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007; 39:347 - 351
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Autorino R, Sternberg CN. Metastatic Renal Cell Carcinoma: Recent Advances in the Targeted Therapy Era. Eur Urol 2009; 56:959 - 971
   PubMed Web of Science ®Google Scholar
• Biswas S, Eisen T. Immunotherapeutic strategies in kidney cancer—when TKIs are not enough. Nat Rev Clin Oncol 2009; 6:478 - 487
   PubMed Web of Science ®Google Scholar
• Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24:25 - 35
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9:327 - 337
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061 - 1068
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271 - 2281
   PubMed Web of Science ®Google Scholar
• Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, et al. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006; 66:5549 - 5554
   PubMed Web of Science ®Google Scholar
• Houghton PJ. Everolimus. Clin Cancer Res 2010; 16:1368 - 1372
   PubMed Web of Science ®Google Scholar
• Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8:579 - 591
   PubMed Web of Science ®Google Scholar
• Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 2010; 70:1053 - 1062
   PubMed Web of Science ®Google Scholar
• Mulders P. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. BJU Int 2009; 104:1585 - 1589
   PubMed Web of Science ®Google Scholar
• Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007; 13:3109 - 3114
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009; 27:2278 - 2287
   PubMed Web of Science ®Google Scholar
• Heng DY, Choueiri TK. Non-clear cell renal cancer: features and medical management. J Natl Compr Canc Netw 2009; 7:659 - 665
   PubMed Web of Science ®Google Scholar